Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma: A Prospective, Multicenter Clinical Study

NCT07522879 is registered in ClinicalTrials.gov with Eye & ENT Hospital of Fudan University as lead sponsor.

NCT NCT07522879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07522879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma: A Prospective, Multicenter Clinical Study
Lead sponsor
Eye & ENT Hospital of Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
April 28, 2026
Completion date
July 1, 2030
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, sinonasal carcinoma